Article Text

PDF
Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas
  1. C B Nunes1,
  2. R M Rocha1,
  3. J S Reis-Filho2,
  4. M B Lambros2,
  5. G F S Rocha1,
  6. F S F Sanches1,
  7. F N Oliveira1,
  8. H Gobbi1
  1. 1
    Department of Anatomic Pathology, Federal University of Minas Gerais, Belo Horizonte, Brazil
  2. 2
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
  1. Dr C B Nunes, Avenida Alfredo Balena 190, sala 305 Belo Horizonte, CEP 30130-100, MG Brazil; cristianabnunes{at}gmail.com

Abstract

Aims: To compare the sensitivity and specificity of new rabbit monoclonal antibody SP3 with those of mouse monoclonal and rabbit polyclonal antibodies using HER2 amplification defined by chromogenic in situ hybridisation (CISH) as the gold standard.

Methods: Serial sections from tissue microarrays (TMAs) containing 84 breast carcinomas were submitted to CISH (Zymed HER2 Spot-Light kit) and immunohistochemistry, using NeoMarkers SP3 (rabbit monoclonal), DAKO A0485 and DAKO HercepTest (polyclonal), Novocastra NCL-CB11, Cell Marque CM-CB11, and Genentech 4D5 (mouse monoclonal).

Results: The best antibody concordance was between SP3 and HercepTest (κ = 0.74). SP3, A0485 and HercepTest detected all HER2 amplified tumours, but were less specific than mouse monoclonal antibodies. 3/38 (7.9%) and 8/38 (21.0%) non-amplified tumours were scored as 3+ using SP3 and A0485, respectively. 3/46 (6.5%) amplified tumours were negative for NCL-CB11. SP3, HercepTest and A0485 showed no gene amplification on 55%, 62.5% and 92.3% of the 2+ scored tumours, but most of the 2+ scored tumours using monoclonal antibodies were amplified by CISH (80–92.3%).

Conclusions: SP3 is more sensitive than mouse monoclonal antibodies for Her2 assessment. However, HercepTest, CB11 and 4D5 show higher specificity than SP3 for the identification of HER2 gene amplification. Mouse monoclonal antibodies show less Her2 2+ tumours; most are amplified by CISH.

Statistics from Altmetric.com

Footnotes

  • Funding: Supported by grants from Fundação de Amparo à Pesquisa do Estado de minas Gerais (FAPEMIG) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). The authors have no relevant financial interest in the products or companies described in this article.

  • Competing interests: None.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.